Advertisement

Topics

Latest "Word & Brown General Agency" News Stories

06:10 EST 23rd February 2019 | BioPortfolio

Here are the most relevant search results for "Word & Brown General Agency" found in our extensive news archives from over 250 global news sources.

More Information about Word & Brown General Agency on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Word & Brown General Agency for you to read. Along with our medical data and news we also list Word & Brown General Agency Clinical Trials, which are updated daily. BioPortfolio also has a large database of Word & Brown General Agency Companies for you to search.

Showing "Word Brown General Agency" News Articles 1–25 of 7,000+

Friday 22nd February 2019

FDA Staff Hammers Karyopharm Cancer Drug on Safety, Efficacy Concerns

A Karyopharm Therapeutics multiple myeloma drug candidate faces longer odds for speedy FDA approval after the agency’s staff raised questions about the therapy’s efficacy and safety. Staff concerns about Karyopharm drug selinexor were detailed in briefing documents posted Friday afternoon, ahead of an advisory committee meeting scheduled for Tuesday. Such panels are convened to assess […...


Moldovan mathematician among academics running in general election

Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $100 million. Urovant plans to use the proceeds to fund ongoing...


Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at the following investor conferences in March: 8th Annual Leerink Partners...

IIP Operating Partnership, LP Announces Exercise in Full of Option to Purchase Additional Exchangeable Senior Notes

Innovative Industrial Properties, Inc. (the "Company") (NYSE: IIPR) announced today that the initial purchasers in IIP Operating Partnership, LP's (the "Operating Partnership") previously announced private offering of 3.75% Exchangeable Senior Notes due 2024 (the "Notes") exercised in full their option to purchase $18.75 million ...

FDA: Gout Drug Uloric Increases Risk of Death

FRIDAY, Feb. 22, 2019 -- The gout medicine Uloric (febuxostat) carries a higher risk of death than allopurinol, according to the U.S. Food and Drug Administration. The agency said its in-depth review of results from a safety clinical trial found...

Predictive values of colorectal cancer alarm symptoms in the general population: a nationwide cohort study

Minor Updates To US FDA Guidances Aim To Clarify What PMA, 510(k) Applications Should Include

The agency has republished two guidance documents outlining conditions for when it could not accept a 510(k) or PMA application...   

The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients

Paladin Labs Announces Approval of Envarsus PA™ in Canada

Paladin Labs and Endo Ventures, subsidiaries of Endo International (NASDAQ:ENDP) have announced that Health Canada’s approval of Envarsus PA is marketed in Canada by Paladin Labs. As quoted in the press release: “We are pleased to announce Health Canada’s approval of Envarsus PA™ in Canada,” said Livio Di Francesco, Vice President & General Manager of Paladin Labs ...

Notice Convening the Annual General Meeting

February 22, 2019 Announcement no. 3      NOTICE CONVENING THE ANNUAL GENERAL MEETING The Board of Directors hereby convenes the Annual General Meeting of BioPorto A / S (the “Company”):   March 18, 2019, at 3.00 pm (CET), At the … Continue reading →

Thought-Controlled Prosthetics Get US FDA 'Leapfrog' Treatment

A new "leapfrog" draft guidance from the US agency addresses implanted brain-computer interface prosthetic devices, and, specifically, the information sponsors...   

Abortion: RCGP supports decriminalisation

The UK Council of the Royal College of General Practitioners has passed a motion to support the decriminalisation of abortion. The college said that abortion should be governed by medical regulatory...

MEDICLIN increased its Group sales by about 6 % - Preliminary Group EBIT amounts to EUR 15.1 mill

DGAP-News: MediClin AG / Key word(s): Preliminary Results 22.02.2019 / 16:12 The issuer is solely responsible for the content of this announcement. Offenburg, 22 February 2019 MEDICLIN increased its Group sales by about 6 % - Preliminary Group EBIT amounts to EUR 15.1 mill. MEDICLIN Aktiengesellschaft (MEDICLIN) has achieved Group sales of EUR 645.1 mill. (previous year: EUR 609.1 mil...

AchievaMed Leads Charge to Provide Exclusively Domestic MSO Services

With health plans facing increased scrutiny for utilizing offshore resources, Managed Service Organizations will struggle to pivot and meet compliance requirements AchievaMed, a leading Managed Services Organization (MSO), is standing firm in their commitment to employing domestic talent in servicing their growing portfolio of medical group and health ...

Nigel Clarke: 'Pharmacy isn’t just handing over a bag of medicine'

The chair of the General Pharmaceutical Council’s plans to revamp pharmacy training, the regulation of online pharmacy and data which show white pharmacists are less likely to be struck off the register.

Magellan Health to Consider Director Nominations

Magellan Health, Inc. (NASDAQ: MGLN) today acknowledged that Starboard Value LP (“Starboard”) has provided notice of its intent to nominate six candidates to stand for election to the Board of Directors at the Company’s 2019 Annual Meeting of Shareholders. Starboard stated that it expects that five of the Company's nine current Board members will be ...

Leading Prenatal App Babyscripts Receives Award from HRSA's Maternal and Child Health Bureau (MCHB)

Babyscripts selected as a Phase 1 winner in MCHB’s Grand Challenge: Remote Pregnancy Monitoring WASHINGTON (PRWEB) February 22, 2019 Babyscripts, the leading virtual care platform for managing obstetrics, was announced as a winner in Phase 1 of the Health Resources and Services Administration’s (HRSA) Maternal and Child Health Bureau (MCHB) Remote Pregnancy Monitoring Challenge on February 19...

Wolf Greenfield Shareholder Edward Gates Earns Client Choice Award from Lexology

Intellectual property law firm Wolf Greenfield is pleased to announce that shareholder Edward Gates has been named as the Exclusive Winner of the Healthcare & Life Sciences Category for Massachusetts in Lexology’s 2019 Client Choice Awards. The Client Choice Awards recognize partners who add real value to their clients’ business. Nomi

Judge Appears Willing To Consider Expanding Court Order For Government To Identify All Separated Immigrant Families

“When there’s an allegation of wrong on this scale, one of the most fundamental obligations of law is to determine the scope of the wrong,” U.S. District Judge Dana Sabraw said. “It is important to recognize we are talking about human beings.” ACLU has asked Sabraw to expand the court order, citing an inspector general report that estimated the separations go far beyond the 2,700 already...

Imbrium Therapeutics Announces U.S. FDA Orphan Drug Designation for Etoposide Toniribate for the Treatment of Relapsed Refractory Biliary Tract Cancer

Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P., in conjunction with Mundipharma EDO GmbH, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its investigational drug etoposide toniribate, a novel topoisomerase II inhibitor, for t...

Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer

Biliary tract cancer or cholangiocarcinoma is rare, when patients fail first-line chemotherapy there are limited treatment options and in most cases the standard of care is palliative1,2 Etoposide toniribate is to be accelerated through a Phase III trial, with the aim of providing a potential additional treatment option in t...

Roswell Park Presentations at TCT Meeting Focus on Tools for Predicting Patient Outcomes

Roswell Park Comprehensive Cancer Center experts were invited to highlight ways to optimize the care of patient undergoing hematopoietic stem cell transplantation, also known as bone marrow transplant, during the TCT/Transplantation and Cellular Therapy Meetings now underway in Houston, Texas. HOUSTON (PRWEB) February 22, 2019 Particularly in the realm of cancer care, which can mean years of trea...

Point-of-Care Ultrasound in General Practice

General practitioners are increasingly using point-of-care ultrasound. What are they using it for, how well are they being trained, and what is the quality of the results? Annals of Family Medicine

Early-stage osteoarthritis drug wins prestigious innovation award

UK-based biotech company rewarded for unique approach to drug development by UK Government’s innovation bodyAKL Research and Development (AKLRD) today announces its investigational medicine for osteoarthritis (OA) has been awarded a prestigious grant from Innovate UK, the leading government innovation agency.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks